Cynata Receives Notice of Allowance received from US Patent Office for Novel MSC Manufacturing Technology
Melbourne, Australia; 11 November 2022: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for a patent application covering its proprietary Cymerus™ mesenchymal stem cell (MSC) platform technology.
The patent application entitled “Pluripotent Stem Cell Assay” is wholly owned by Cynata and describes a novel method for ensuring quality and purity of Cynata’s finished therapeutic MSC products.
The Notice of Allowance is sent to the applicant when the USPTO intends to issue a patent. The patent adds to the existing broad and comprehensive IP protection of the Cymerus manufacturing platform and its unique ability to yield highly consistent MSCs at scale, from a single donation, to create therapeutic stem cell products.
Dr Kilian Kelly, Cynata’s Chief Operating Officer, said: “We are delighted that our product development activities have resulted in yet a further patent, particularly in the USA, a key commercial jurisdiction. This important achievement adds to our portfolio of wholly-Cynata owned patents and patent applications, providing further protection over our proprietary Cymerus technology to 2037 and beyond. The novel method described in the patent specification and patent claims enhances our competitive position around the Cymerus platform which enables the production of consistent, high-quality mesenchymal stem cells at scale. These important characteristics afford a major competitive advantage in the ongoing development of off-the-shelf therapeutic stem cell products to target a range of devastating diseases worldwide”.
Cynata anticipates that the patent will be granted around February 2023, with an expiration date of 15 November 2037.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)